Palatin Technologies Has Started Patient Dosing In Phase 2 Study Of Bremelanotide Co-administered With Tirzepatide For Obesity, Complete Enrollment Is Currently Expected In 3Q 2024, With Topline Data Expected In Q1 Calendar Year 2025
Portfolio Pulse from Benzinga Newsdesk
Palatin Technologies has initiated patient dosing in a Phase 2 study of Bremelanotide co-administered with Tirzepatide for obesity. Enrollment is expected to complete in Q3 2024, with topline data anticipated in Q1 2025.
August 22, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palatin Technologies has started dosing patients in a Phase 2 study for obesity treatment, with results expected in early 2025. This could impact PTN's stock as the study progresses.
The initiation of a Phase 2 study is a significant milestone for Palatin Technologies, potentially leading to positive stock movement as the study progresses and results are anticipated. The timeline for completion and data release provides a clear roadmap for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90